-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES SOVLEPLENIB GRANTED US FDA ORPHAN DRUG DESIGNATION FOR PRIMARY IMMUNE THROMBOCYTOPENIA

Reuters·10/29/2026 00:02:03